IMCR Key Statistics, Chart & Performance
The current stock price of IMCR is 36.02 USD. In the past month the price increased by 0.19%. In the past year, price increased by 27.17%.
IMCR Latest News, Press Relases and Analysis
IMCR Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.07 | 401.99B | ||
| AMGN | AMGEN INC | 14.87 | 175.17B | ||
| GILD | GILEAD SCIENCES INC | 14.63 | 148.61B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.25 | 115.62B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.72 | 79.10B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 767.65 | 51.72B | ||
| INSM | INSMED INC | N/A | 42.00B | ||
| NTRA | NATERA INC | N/A | 31.52B | ||
| BIIB | BIOGEN INC | 10.5 | 25.78B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.96 | 21.54B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.31B | ||
| INCY | INCYTE CORP | 15.36 | 19.37B |
Related stock screener links
About IMCR
Company Profile
Immunocore Holdings Plc operates as a commercial-stage biotechnology company pioneering the development of a novel class of TCR bispecific immunotherapies called ImmTAX – Immune mobilizing monoclonal TCRs Against X disease. The company is headquartered in Abingdon, Oxfordshire and currently employs 493 full-time employees. The company went IPO on 2021-02-05. The firm is engaged in the development of TCR bispecific immunotherapies, ImmTAX, which immunes mobilizing monoclonal TCRs against X disease, designed to treat a range of diseases, including cancer, autoimmune and infectious disease. The firm has a pipeline of clinical-stage programs in oncology and infectious diseases, as well as numerous pre-clinical projects. Its lead product, KIMMTRAK, is a TCR therapeutic for the treatment of patients with unresectable or metastatic uveal melanoma (mUM), in the United States, European Union, Canada, Australia and the United Kingdom. Its pipeline products include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-M113V, IMC-I109V, IMC-S118AI, and IMC-U120AI, among others. Its clinical programs are being conducted with patients with a range of cancers including melanoma, ovarian, lung, colorectal and others.
Company Info
IMMUNOCORE HOLDINGS PLC-ADR
92 Park Drive Milton Park
Abingdon OXFORDSHIRE OX14 4RY GB
CEO: Bahija Jallal
Employees: 493
Phone: 441235438600
IMMUNOCORE HOLDINGS PLC-ADR / IMCR FAQ
What does IMMUNOCORE HOLDINGS PLC-ADR do?
Immunocore Holdings Plc operates as a commercial-stage biotechnology company pioneering the development of a novel class of TCR bispecific immunotherapies called ImmTAX – Immune mobilizing monoclonal TCRs Against X disease. The company is headquartered in Abingdon, Oxfordshire and currently employs 493 full-time employees. The company went IPO on 2021-02-05. The firm is engaged in the development of TCR bispecific immunotherapies, ImmTAX, which immunes mobilizing monoclonal TCRs against X disease, designed to treat a range of diseases, including cancer, autoimmune and infectious disease. The firm has a pipeline of clinical-stage programs in oncology and infectious diseases, as well as numerous pre-clinical projects. Its lead product, KIMMTRAK, is a TCR therapeutic for the treatment of patients with unresectable or metastatic uveal melanoma (mUM), in the United States, European Union, Canada, Australia and the United Kingdom. Its pipeline products include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-M113V, IMC-I109V, IMC-S118AI, and IMC-U120AI, among others. Its clinical programs are being conducted with patients with a range of cancers including melanoma, ovarian, lung, colorectal and others.
Can you provide the latest stock price for IMMUNOCORE HOLDINGS PLC-ADR?
The current stock price of IMCR is 36.02 USD. The price decreased by -2.12% in the last trading session.
Does IMMUNOCORE HOLDINGS PLC-ADR pay dividends?
IMCR does not pay a dividend.
What is the ChartMill technical and fundamental rating of IMCR stock?
IMCR has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
What is the analyst forecast for IMCR stock?
23 analysts have analysed IMCR and the average price target is 69.09 USD. This implies a price increase of 91.8% is expected in the next year compared to the current price of 36.02.
Can you provide the upcoming earnings date for IMMUNOCORE HOLDINGS PLC-ADR?
IMMUNOCORE HOLDINGS PLC-ADR (IMCR) will report earnings on 2026-02-24, after the market close.
IMCR Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to IMCR. When comparing the yearly performance of all stocks, IMCR is one of the better performing stocks in the market, outperforming 82.7% of all stocks.
IMCR Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to IMCR. IMCR scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
IMCR Financial Highlights
Over the last trailing twelve months IMCR reported a non-GAAP Earnings per Share(EPS) of -0.57. The EPS increased by 40% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -2.65% | ||
| ROE | -7.37% | ||
| Debt/Equity | 0.99 |
IMCR Forecast & Estimates
23 analysts have analysed IMCR and the average price target is 69.09 USD. This implies a price increase of 91.8% is expected in the next year compared to the current price of 36.02.
For the next year, analysts expect an EPS growth of 59.52% and a revenue growth 27.67% for IMCR